Literature DB >> 17154294

Cdc42 is implicated in polarity during meiotic resumption and blastocyst formation in the mouse.

Xiang-Shun Cui1, Xing-Yu Li, Nam-Hyung Kim.   

Abstract

Cell division cycle 42 (Cdc42), a member of the Rho family of small guanosine triphosphatase (GTPase) proteins, regulates multiple cell functions, including: motility, proliferation, apoptosis, and cell morphology. In order to obtain insight into the role of Cdc42 in meiotic resumption and embryo development, we first evaluated its gene expression levels in mouse oocytes and embryos during in vitro development. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) revealed high-expression levels in GV stage oocytes that steadily decreased up to the 2-cell (2C) stage embryo, and then expression increased during morulae and blastocyst formation. Indirect Immunocytochemistry also showed protein synthesis of CDC42 in the mouse oocytes and early embryos. Introducing small interference RNA (siRNA) of Cdc42 into germinal vesicle stage oocytes or zygotes specifically reduced both mRNA expression and protein synthesis of CDC42 in in vitro developed metaphase II oocytes and early embryos. Meiotic maturation and cytoskeleton assembly were significantly altered following siRNA injection into germinal vesicle stage oocytes. Injection of siRNA into the zygote did not affect cleavage or cell numbers in morulae, but significantly decreased in vitro development to the morula or blastocyst. These findings suggest that gene expression of Cdc42 is involved in meiotic resumption and blastocyst formation in the mouse, possibly through maintaining polarity. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17154294     DOI: 10.1002/mrd.20571

Source DB:  PubMed          Journal:  Mol Reprod Dev        ISSN: 1040-452X            Impact factor:   2.609


  9 in total

1.  Statins inhibit blastocyst formation by preventing geranylgeranylation.

Authors:  Vernadeth B Alarcon; Yusuke Marikawa
Journal:  Mol Hum Reprod       Date:  2016-02-07       Impact factor: 4.025

2.  Involvement of LIMK1/2 in actin assembly during mouse embryo development.

Authors:  Xing Duan; Hao-Lin Zhang; Lan-Lan Wu; Meng-Yao Liu; Meng-Hao Pan; Xiang-Hong Ou; Shao-Chen Sun
Journal:  Cell Cycle       Date:  2018-07-25       Impact factor: 4.534

3.  Small GTPase RhoA regulates cytoskeleton dynamics during porcine oocyte maturation and early embryo development.

Authors:  Yu Zhang; Xing Duan; Rui Cao; Hong-Lin Liu; Xiang-Shun Cui; Nam-Hyung Kim; Rong Rui; Shao-Chen Sun
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

4.  Small GTPases and formins in mammalian oocyte maturation: cytoskeletal organizers.

Authors:  Sojung Kwon; Hyunjung J Lim
Journal:  Clin Exp Reprod Med       Date:  2011-03-31

5.  Transcriptomic features of Pecten maximus oocyte quality and maturation.

Authors:  Marianna Pauletto; Massimo Milan; Arnaud Huvet; Charlotte Corporeau; Marc Suquet; Josep V Planas; Rebeca Moreira; Antonio Figueras; Beatriz Novoa; Tomaso Patarnello; Luca Bargelloni
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

Review 6.  "Biomechanical Signaling in Oocytes and Parthenogenetic Cells".

Authors:  Georgia Pennarossa; Fulvio Gandolfi; Tiziana A L Brevini
Journal:  Front Cell Dev Biol       Date:  2021-02-11

Review 7.  Advances in the study of CDC42 in the female reproductive system.

Authors:  Qiaojuan Mei; Huiying Li; Yu Liu; Xiaofei Wang; Wenpei Xiang
Journal:  J Cell Mol Med       Date:  2021-12-03       Impact factor: 5.310

8.  Polarized Cdc42 activation promotes polar body protrusion and asymmetric division in mouse oocytes.

Authors:  Benoit Dehapiot; Virginie Carrière; John Carroll; Guillaume Halet
Journal:  Dev Biol       Date:  2013-02-04       Impact factor: 3.582

9.  Sperm miRNAs- potential mediators of bull age and early embryo development.

Authors:  Chongyang Wu; Patrick Blondin; Christian Vigneault; Rémi Labrecque; Marc-André Sirard
Journal:  BMC Genomics       Date:  2020-11-16       Impact factor: 3.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.